What is OncoSec Medical Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OncoSec Medical's cash to debt ratio for the quarter that ended in Jan. 2023 was 1.06.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, OncoSec Medical could pay off its debt using the cash in hand for the quarter that ended in Jan. 2023.
The historical rank and industry rank for OncoSec Medical's Cash-to-Debt or its related term are showing as below:
OncoSec Medical Cash-to-Debt Historical Data
The historical data trend for OncoSec Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OncoSec Medical Cash-to-Debt Chart
|
OncoSec Medical Annual Data
|
|
Trend |
Jul13 |
Jul14 |
Jul15 |
Jul16 |
Jul17 |
Jul18 |
Jul19 |
Jul20 |
Jul21 |
Jul22 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
No Debt |
299.38 |
2.60 |
6.28 |
1.99 |
|
OncoSec Medical Quarterly Data
|
|
Apr18 |
Jul18 |
Oct18 |
Jan19 |
Apr19 |
Jul19 |
Oct19 |
Jan20 |
Apr20 |
Jul20 |
Oct20 |
Jan21 |
Apr21 |
Jul21 |
Oct21 |
Jan22 |
Apr22 |
Jul22 |
Oct22 |
Jan23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
4.05 |
3.47 |
1.99 |
1.11 |
1.06 |
Competitive Comparison of OncoSec Medical's Cash-to-Debt
For the Biotechnology subindustry, OncoSec Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSec Medical's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoSec Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where OncoSec Medical's Cash-to-Debt falls into.
OncoSec Medical Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
OncoSec Medical's Cash to Debt Ratio for the fiscal year that ended in Jul. 2022 is calculated as:
OncoSec Medical's Cash to Debt Ratio for the quarter that ended in Jan. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSec Medical (OncoSec Medical) Business Description
Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
| Robert J Delaversano |
officer: Principal Accounting Officer |
217 W. MAIN STREET, SOMERVILLE NJ 08876 |
| Spahr Stephany Foster |
director |
C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
| Robert H. Arch |
officer: President and CEO |
C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
| George Chi |
officer: Chief Financial Officer |
9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
| Lin Shi |
director |
24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218 |
| Margaret Dalesandro |
director |
ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
| Yuhang Zhao |
director |
6 HORTON DR., CHESTER NJ 07930 |
| Brian A Leuthner |
officer: Chief Operating Officer |
200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
| Daniel J. O'connor |
director |
C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
| China Grand Pharmaceutical & Healthcare Holdings Ltd |
10 percent owner, other: See Remarks |
UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000 |
| Alpha Holdings, Inc. |
director, 10 percent owner |
GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016 |
| Kellie Malloy Foerter |
officer: Chief Operating Officer |
C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218 |
| Herbert Kim Lyerly |
director |
C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218 |
| Chao Zhou |
director |
UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000 |
| Grand Decade Developments Ltd |
10 percent owner, other: See Remarks |
UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000 |
OncoSec Medical (OncoSec Medical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCSQ has been successfully added to your